JY
EWTX icon

Jeff Yass’s Edgewise Therapeutics EWTX Stock Holding History

Jeff Yass’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Sell
5,692
-20,982
-79% -$723K ﹤0.01% 11646
2026
Q1 		$840K Sell
26,674
-43,522
-62% -$1.26M ﹤0.01% 8350
2025
Q4 		$1.74M Buy
70,196
+24,561
+54% +$493K ﹤0.01% 5933
2025
Q3 		$740K Sell
45,635
-69,635
-60% -$988K ﹤0.01% 8069
2025
Q2 		$1.51M Sell
115,270
-61,396
-35% -$885K ﹤0.01% 6424
2025
Q1 		$3.89M Buy
176,666
+144,953
+457% +$3.8M ﹤0.01% 4129
2024
Q4 		$847K Sell
31,713
-168,787
-84% -$5.37M ﹤0.01% 7382
2024
Q3 		$5.35M Buy
200,500
+183,724
+1,095% +$3.65M ﹤0.01% 3485
2024
Q2 		$302K Sell
16,776
-10,094
-38% -$176K ﹤0.01% 9434
2024
Q1 		$490K Sell
26,870
-27,566
-51% -$438K ﹤0.01% 8562
2023
Q4 		$596K Buy
+54,436
New +$382K ﹤0.01% 8233
2023
Q3 		– Sell
-11,735
Closed -$90.9K – 12262
2023
Q2 		$90.9K Sell
11,735
-5,150
-31% -$43.4K ﹤0.01% 11019
2023
Q1 		$113K Buy
+16,885
New +$157K ﹤0.01% 11193

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's EWTX Position: Q2 2026 in Review

Jeff Yass reduced its Edgewise Therapeutics (EWTX) stake by 79% in Q2 2026, selling an estimated $723K and leaving 5,692 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11646.

Jeff Yass first reported a position in EWTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.35M in Q3 2024. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Jeff Yass held 5,692 shares of Edgewise Therapeutics worth $231K as of Q2 2026.
  • Jeff Yass sold 20,982 Edgewise Therapeutics shares in Q2 2026, an estimated $723K.
  • Edgewise Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11646 holding.
  • Jeff Yass first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Jeff Yass's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.